Loading…
Reported covered position: Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
THE AMERICAN COLLEGE OF LIFESTYLE MEDICINE (ACLM) via VENN STRATEGIES
2026 · third_quarter · Q3
Reimbursement and education around lifestyle medicine.
Issues related to nutrition, physical activity, sleep, stress management, connectedness, and risky substance avoidance
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| AMERINET INC |
| 6 |
| 2015 |
| ASSERTIO THERAPEUTICS | 6 | 2018–2019 |
| ELI LILLY AND COMPANY | 6 | 2016–2017 |
| PRIMARY CARE COLLABORATIVE | 6 | 2025–2026 |
| AVANIR PHARMACEUTICALS, INC. | 5 | 2021 |
| EMPLOYEE-OWNED S CORPORATIONS OF AMERICA | 5 | 2015–2017 |
| AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS | 4 | 2021 |
| THE AMERICAN COLLEGE OF LIFESTYLE MEDICINE (ACLM) | 4 | 2026 |
| UCB, INC. | 3 | 2021 |
| CHARTED COURSE | 1 | 2022 |
| PARTNERSHIP FOR PART D ACCESS | 1 | 2021 |
2026 · third_quarter · Q3
Primary care payments.
Primary care payments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIMARY CARE COLLABORATIVE via VENN STRATEGIES
2026 · second_quarter · Q2
Primary care payments.
Primary care payments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE AMERICAN COLLEGE OF LIFESTYLE MEDICINE (ACLM) via VENN STRATEGIES
2026 · second_quarter · Q2
Reimbursement and education around lifestyle medicine.
Issues related to nutrition, physical activity, sleep, stress management, connectedness, and risky substance avoidance
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PRIMARY CARE COLLABORATIVE via VENN STRATEGIES
2026 · first_quarter · Q1
Primary care payments.
Primary care payments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE AMERICAN COLLEGE OF LIFESTYLE MEDICINE (ACLM) via VENN STRATEGIES
2026 · first_quarter · Q1
Reimbursement and education around lifestyle medicine.
Reimbursement and education around lifestyle medicine.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE AMERICAN COLLEGE OF LIFESTYLE MEDICINE (ACLM) via VENN STRATEGIES
2026 · first_quarter · RR
Reimbursement and education around lifestyle medicine
PRIMARY CARE COLLABORATIVE via VENN STRATEGIES
2025 · fourth_quarter · Q4
Primary care payments.
Primary care payments.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
PRIMARY CARE COLLABORATIVE via VENN STRATEGIES
2025 · third_quarter · Q3
Primary care payments
Primary care payments
Filing targets: Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
PRIMARY CARE COLLABORATIVE via VENN STRATEGIES
2025 · third_quarter · RR
Primary care payments.
Primary care payments.
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2023 · first_quarter · Q1
General policy issues relating to academic medicine.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2022 · fourth_quarter · Q4
General policy issues relating to academic medicine.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FUTURE OF PHARMACY COALITION via VENN STRATEGIES
2022 · fourth_quarter · 4T
Ensuring access to vital pharmacist services.
Ensuring access to vital pharmacist services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FUTURE OF PHARMACY COALITION via VENN STRATEGIES
2022 · third_quarter · Q3
Ensuring access to vital pharmacist services.
Ensuring access to vital pharmacist services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2022 · third_quarter · Q3
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2022 · third_quarter · Q3
General policy issues relating to academic medicine.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHARTED COURSE via VENN STRATEGIES
2022 · third_quarter · RR
Workforce preparedness issues, nurse staffing levels, and pandemic preparedness.
Workforce preparedness issues, nurse staffing levels, and pandemic preparedness.
Workforce preparedness issues, nurse staffing levels, and pandemic preparedness.
FUTURE OF PHARMACY COALITION via VENN STRATEGIES
2022 · second_quarter · Q2
Ensuring access to vital pharmacist services.
Ensuring access to vital pharmacist services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2022 · second_quarter · Q2
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2022 · second_quarter · Q2
General policy issues relating to academic medicine.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FUTURE OF PHARMACY COALITION via VENN STRATEGIES
2022 · first_quarter · Q1
Ensuring access to vital pharmacist services.
Ensuring access to vital pharmacist services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2022 · first_quarter · Q1
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2022 · first_quarter · Q1
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FUTURE OF PHARMACY COALITION via VENN STRATEGIES
2021 · fourth_quarter · 4A
Ensuring access to vital pharmacist services.
Ensuring access to vital pharmacist services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FUTURE OF PHARMACY COALITION via VENN STRATEGIES
2021 · fourth_quarter · Q4
Ensuring access to vital pharmacist services.
Ensuring access to vital pharmacist services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS via VENN STRATEGIES
2021 · fourth_quarter · 4T
Advocating for policies that will increase the ability of pharmacists to serve patients.
Advocating for policies that will increase the ability of pharmacists to serve patients.
Advocating for policies that will increase the ability of pharmacists to serve patients.
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · fourth_quarter · Q4
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2021 · fourth_quarter · Q4
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2021 · fourth_quarter · Q4
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Q3
Issues regarding FDA PDUFA procedures in COVID.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · third_quarter · Q3
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS via VENN STRATEGIES
2021 · third_quarter · Q3
Advocating for policies that will increase the ability of pharmacists to serve patients.
Advocating for policies that will increase the ability of pharmacists to serve patients.
Advocating for policies that will increase the ability of pharmacists to serve patients.
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2021 · third_quarter · Q3
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FUTURE OF PHARMACY COALITION via VENN STRATEGIES
2021 · third_quarter · Q3
Ensuring access to vital pharmacist services.
Ensuring access to vital pharmacist services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2021 · third_quarter · Q3
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FUTURE OF PHARMACY COALITION via VENN STRATEGIES
2021 · third_quarter · RR
Medicare coverage of pharmacy services during and after the public health emergency.
Medicare coverage of pharmacy services during and after the public health emergency.
2021 · second_quarter · Q2
Matters related to innovation in, and patient access to, biopharmaceutical therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · second_quarter · Q2
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2021 · second_quarter · Q2
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2021 · second_quarter · Q2
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS via VENN STRATEGIES
2021 · second_quarter · Q2
Advocating for policies that will increase the ability of pharmacists to serve patients.
Advocating for policies that will increase the ability of pharmacists to serve patients.
Advocating for policies that will increase the ability of pharmacists to serve patients.
AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS via VENN STRATEGIES
2021 · second_quarter · RR
Advocating for policies that will increase the ability of pharmacists to serve patients.
Advocating for policies that will increase the ability of pharmacists to serve patients.
Advocating for policies that will increase the ability of pharmacists to serve patients.
PARTNERSHIP FOR PART D ACCESS via VENN STRATEGIES
2021 · second_quarter · RR
Issues related to protecting access to needed medications under the Medicare Part D program, notably the six protected classes.
2021 · second_quarter · RR
Matters related to innovation in, and patient access to, biopharmaceutical therapies.
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · first_quarter · Q1
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2021 · first_quarter · Q1
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2021 · first_quarter · Q1
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · first_quarter · RR
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2020 · fourth_quarter · Q4
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2020 · fourth_quarter · Q4
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2020 · third_quarter · Q3
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2020 · third_quarter · Q3
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2020 · second_quarter · Q2
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2020 · second_quarter · Q2
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2020 · first_quarter · Q1
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2020 · first_quarter · Q1
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2019 · fourth_quarter · 4A
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2019 · fourth_quarter · Q4
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2019 · fourth_quarter · Q4
Health care issues related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2019 · fourth_quarter · Q4
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2019 · first_quarter · 1A
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2019 · second_quarter · 2A
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2019 · second_quarter · 2A
Health care issues related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ASSERTIO THERAPEUTICS via VENN STRATEGIES
2019 · third_quarter · Q3
Promoting policies that support patient access to therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2019 · third_quarter · Q3
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2019 · third_quarter · Q3
Health care issues related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2019 · third_quarter · Q3
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2019 · second_quarter · Q2
Tax issues affecting publicly traded biotechnology companies
General issues related to the bio-pharmaceutical sector, innovation, patient access, and health care manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ASSERTIO THERAPEUTICS via VENN STRATEGIES
2019 · second_quarter · Q2
Promoting policies that support patient access to therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2019 · second_quarter · Q2
Health care issues related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2019 · second_quarter · Q2
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2019 · second_quarter · Q2
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2019 · first_quarter · 1A
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSERTIO THERAPEUTICS via VENN STRATEGIES
2019 · first_quarter · Q1
Promoting policies that support patient access to therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2019 · first_quarter · Q1
General policy issues relating to academic medicine
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2019 · first_quarter · Q1
Health care issue related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2019 · first_quarter · Q1
General issues related to the bio-pharmaceutical sector, innovation, patient access, and health care manufacturing.
Tax issues affecting publicly traded biotechnology companies
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2019 · first_quarter · Q1
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2018 · first_quarter · 1A
General issues related to the bio-pharmaceutical sector, innovation, and health care manufacturing.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2018 · first_quarter · 1A
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2018 · second_quarter · 2A
General issues related to the bio-pharmaceutical sector, innovation, and health care manufacturing.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ASSERTIO THERAPEUTICS via VENN STRATEGIES
2018 · fourth_quarter · Q4
Promoting policies that support patient access to therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2018 · fourth_quarter · Q4
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2018 · fourth_quarter · Q4
Health care issue related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2018 · fourth_quarter · Q4
General issues related to the bio-pharmaceutical sector, innovation, patient access, and health care manufacturing.
Tax issues affecting publicly traded biotechnology companies.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2018 · fourth_quarter · Q4
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2018 · third_quarter · Q3
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2018 · third_quarter · Q3
Health care issue related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ASSERTIO THERAPEUTICS via VENN STRATEGIES
2018 · third_quarter · Q3
Promoting policies that support biopharmaceutical innovation and competition.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2018 · third_quarter · Q3
General issues related to the bio-pharmaceutical sector, innovation, and health care manufacturing.
Tax issues affecting publicly traded biotechnology companies.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2018 · third_quarter · Q3
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSERTIO THERAPEUTICS via VENN STRATEGIES
2018 · third_quarter · RR
Promoting policies that support biopharmaceutical innovation and competition.
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2018 · second_quarter · Q2
General issues related to the bio-pharmaceutical sector, innovation, and health care manufacturing.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2018 · second_quarter · Q2
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2018 · second_quarter · Q2
Health care issue related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2018 · second_quarter · Q2
Improving access to non-opioid approaches to pain management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR HOME DIALYSIS via VENN STRATEGIES
2018 · first_quarter · Q1
Health care issue related to home dialysis services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2018 · first_quarter · Q1
General issues related to the bio-pharmaceutical sector, innovation, and health care manufacturing.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION/UW HEALTH via VENN STRATEGIES
2018 · first_quarter · Q1
General policy issues relating to academic medicine.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PACIRA PHARMACEUTICALS INC. via VENN STRATEGIES
2018 · second_quarter · RR
Improving access to non-opioid approaches to pain management.
Advocating for policies that will increase the ability of pharmacists to serve patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
Advocating for policies that will increase the ability of pharmacists to serve patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Health & Human Services, Dept of (HHS)
Advocating for policies that will increase the ability of pharmacists to serve patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Health & Human Services, Dept of (HHS)
Advocating for policies that will increase the ability of pharmacists to serve patients.